The future of precision medicine

Abstract Translational omics refers to the effective deployment of genomics- and other omics-derived molecular information, to the clinical setting, in order to make conventional medicine more precise. The overarching ambition of precision medicine is, therefore, to seamlessly integrate biomolecular data from omics fields with clinical data. Fueled by advances in computational science, including machine learning and more recently deep learning approaches, we can expect exponential growth in discoveries in terms of markers of disease susceptibility, diagnosis, prognosis, and therapy. However, with such an unprecedented volume of discovery on the horizon, maintaining the highest possible standards of research, quality and integrity will become even more critical to ensuring an effective transition to precision medicine.

• Publication year

  2020

• Venue

  Precision Medicine for Investigators, Practitioners and Providers

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Computer Science

• Identifiers
  DOI 10.1016/b978-0-12-819178-1.00054-x
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Translational -omics: Future potential and current challenges in precision medicine.

  2018cited by this paper
• Precision Medicine: From Science To Value.

  2018cited by this paper
• Detection and localization of surgically resectable cancers with a multi-analyte blood test

  2018cited by this paper
• A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia

  2018cited by this paper
• Natural Language Processing and Its Implications for the Future of Medication Safety: A Narrative Review of Recent Advances and Challenges

  2018cited by this paper
• Surgery 3.0, artificial intelligence and the next‐generation surgeon

  2018cited by this paper
• SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

  2018cited by this paper
• The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing.

  2017cited by this paper
• Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity

  2016cited by this paper
• Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.

  2016cited by this paper
• Ethical, legal and social implications of incorporating personalized medicine into healthcare.

  2015cited by this paper
• The social licence for research: why care.data ran into trouble

  2015cited by this paper
• Building Highly-Optimized, Low-Latency Pipelines for Genomic Data Analysis

  2015cited by this paper
• Cloud-based bioinformatics workflow platform for large-scale next-generation sequencing analyses

  2014cited by this paper
• Trends in big data analytics

  2014cited by this paper
• Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer.

  2013cited by this paper
• Family Physicians’ Awareness and Knowledge of the Genetic Information Non-Discrimination Act (GINA)

  2012cited by this paper
• Cancer institute tackles sloppy data

  2012cited by this paper
• Preparing for precision medicine.

  2012cited by this paper
• The Patient Protection and Affordable Care Act: Implications for Public Health Policy and Practice

  2011cited by this paper
• Cancer: Missing the mark

  2011cited by this paper
• The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?

  2011cited by this paper
• Predictive, preventive, personalized and participatory medicine: back to the future

  2010cited by this paper
• Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer.

  2010cited by this paper
• Ultrafast and memory-efficient alignment of short DNA sequences to the human genome

  2009cited by this paper
• Docking and chemoinformatic screens for new ligands and targets.

  2009cited by this paper
• Information governance standards for managing e-health information

  2005cited by this paper
• Computer decision support systems.

  2000cited by this paper
• Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system.

  1999cited by this paper
• Nuclear DNA markers in systematics and evolution

  1994cited by this paper

• Approaches of wearable and implantable biosensor towards of developing in precision medicine

  2024cites this paper